Younes N, St-Jean M, Desrochers M, Therasse E, Latour M, Bourdeau I
J Endocr Soc. 2024; 8(10):bvae155.
PMID: 39301312
PMC: 11411212.
DOI: 10.1210/jendso/bvae155.
Holaj R, Waldauf P, Wichterle D, Kvasnicka J, Zelinka T, Petrak O
Diagnostics (Basel). 2022; 12(7).
PMID: 35885622
PMC: 9315939.
DOI: 10.3390/diagnostics12071718.
Guo Z, Nanba K, Udager A, McWhinney B, Ungerer J, Wolley M
J Clin Endocrinol Metab. 2020; 105(9).
PMID: 32516371
PMC: 7426003.
DOI: 10.1210/clinem/dgaa367.
Leung H, Woo Y, Fong C, Tan K, Lau E, Chan K
J Endocrinol Invest. 2019; 43(3):347-355.
PMID: 31529391
DOI: 10.1007/s40618-019-01114-6.
Hardege I, Xu S, Gordon R, Thompson A, Figg N, Stowasser M
Mol Endocrinol. 2015; 29(10):1522-30.
PMID: 26340408
PMC: 5414677.
DOI: 10.1210/me.2015-1195.
Mineralocorticoid hypertension.
Gupta V
Indian J Endocrinol Metab. 2011; 15 Suppl 4:S298-312.
PMID: 22145132
PMC: 3230101.
DOI: 10.4103/2230-8210.86972.
Diagnosis and surgical management for primary hyperaldosteronism.
Munver R, Yates J
Curr Urol Rep. 2010; 11(1):51-7.
PMID: 20425638
DOI: 10.1007/s11934-009-0081-0.
Differential diagnosis of primary aldosteronism subtypes.
Mulatero P, Bertello C, Verhovez A, Rossato D, Giraudo G, Mengozzi G
Curr Hypertens Rep. 2009; 11(3):217-23.
PMID: 19442332
DOI: 10.1007/s11906-009-0038-1.
A reverse postural test as a screening tool for aldosterone-producing adenoma: a pilot study.
Weickert M, Schofl-Siegert B, Arafat A, Pfeiffer A, Mohlig M, Schofl C
Endocrine. 2009; 36(1):75-82.
PMID: 19399649
DOI: 10.1007/s12020-009-9188-9.
Diagnosis and management of primary aldosteronism.
Wheeler M, Harris D
World J Surg. 2003; 27(6):627-31.
PMID: 12732984
DOI: 10.1007/s00268-003-7069-6.
Hormonal characteristics of primary aldosteronism due to unilateral adrenal hyperplasia.
Otsuka F, Koyama S, Yamanari H, Ogura T, Ohe T, Makino H
J Endocrinol Invest. 1998; 21(8):531-6.
PMID: 9801995
DOI: 10.1007/BF03347340.
Primary aldosteronism.
Gordon R
J Endocrinol Invest. 1995; 18(7):495-511.
PMID: 9221268
DOI: 10.1007/BF03349761.
Therapeutic value of calcium antagonists in autonomous hyperaldosteronism.
Stimpel M, Ivens K, Volkmann H, Wambach G, Kaufmann W
Klin Wochenschr. 1989; 67(4):248-52.
PMID: 2648061
DOI: 10.1007/BF01717327.
Activity of [des-aspartyl1]-angiotensin II in primary aldosteronism.
Carey R, Ayers C, Vaughan Jr E, Peach M, Herf S
J Clin Invest. 1979; 63(4):718-26.
PMID: 438332
PMC: 372007.
DOI: 10.1172/JCI109355.
